Histogenics sets IPO terms

Histogenics Corp. (Waltham, Mass.) set terms for its IPO on NASDAQ and now plans to sell 4.3 million shares at $13-$15. At the midpoint, Histogenics would raise $60 million and be valued at $151.1 million. Cowen; Needham; Canaccord Genuity; and BTIG are underwriters.

The company's NeoCart is in Phase III testing to repair knee cartilage defects. NeoCart is an autologous engineered neocartilage implant that integrates the patient's own cartilage cells in a proprietary scaffold. ...